News|Articles|June 19, 2019

Premier Pharmacy Labs Recalls All Unexpired Sterile Products

The company is voluntarily recalling all unexpired products that are intended to be sterile because of a lack of sterility assurance.

Premier Pharmacy Labs announced on June 18, 2019 that it was voluntarily recalling all unexpired products that were intended to be sterile because of a lack of sterility assurance. The recall follows an FDA inspection of the company’s Weeki Wachee, FL facility that found insufficient environmental controls, potential cross contamination, and a lack of process validation.

While the company has not received any reports of adverse events as of date, administration of nonsterile drug products that were intended to be sterile could result in serious infections. The company stated in a press release that the recall was being conducted out of an “abundance of caution.” Adverse events may be reported to FDA through its MedWatch program.

Source: FDA

 


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.